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Introduction
Th   e war between colloids and crystalloids wages on. Th  e 
most recent study of ﬂ   uid prescribing practices in 
critically ill patients, in the previous issue of Critical 
Care, examined data from 5,274 patients in 391 ICUs 
across 25 countries [1]. In so doing, the authors have 
provided a snapshot of global ﬂ  uid resuscitation prescrib-
ing practices. Th  e observation that colloids were more 
frequently prescribed than crystalloids, both on the 
individual patient level and according to ﬂ  uid  resus-
citation episodes, is novel and surprising [2]. More speci-
ﬁ  cally, Finfer and colleagues [1] found colloids were more 
often used for impaired perfusion or low cardiac output, 
and geographically more often used in China, Great 
Britain and Sweden; crystalloids were more frequently 
used in the United States, New Zealand and Italy [1]. Th  e 
study raises a diﬃ     cult question: why are some ICUs 
prescribing colloids more often than crystalloids when 
there is little convincing evidence that colloids are 
superior for ﬂ   uid resuscitation? Asked diﬀ  erently,  do 
colloids provide an advantage over crystalloids in certain 
regions or in speciﬁ  c patient populations that have not 
yet been elucidated?
Is there a rationale for using colloids?
Following a spate of systematic reviews with conﬂ  icting 
conclusions about both the safety and eﬃ   cacy of colloids, 
the American Th  oracic Society released in 2004 a 
consensus statement on colloid use in the critically ill [3]. 
Th  at guideline noted that colloids restore intravascular 
volume and tissue perfusion more rapidly than crystal-
loids in shock states. Th  is is at least in part because 
colloids may be prescribed in volumes equivalent to 
whole blood loss, while crystalloids require 2 to 2.5 times 
greater volume infusion [4]. Does this translate into a 
clinically signiﬁ  cant reduction in resuscitation time?
Perhaps there are speciﬁ   c patient subgroups where 
colloid use may confer an important beneﬁ  t? Colloid use 
in cardiac surgical patients is reported to decrease 
pulmonary edema, pain and need for anti-emetics, with 
consequent faster return of bowel function due to 
decreased gut edema and preserved gut perfusion [5,6]. 
Also in cardiac surgical patients, albumin use has been 
associated with greater peri-operative survival [7]. Th  ere 
is also good clinical evidence for use of colloids in 
dialysis-related hypotension, spontaneous bacterial 
peritonitis and large volume paracentesis [3]. Colloids 
may also be considered in combination with diuretics in 
patients with acute lung injury or acute respiratory 
distress syndrome [8,9]. Finally, albumin administration 
to children with malaria and to adults with sepsis may 
improve survival [10,11]. If these latter two populations 
are conﬁ  rmed to beneﬁ  t from albumin resuscitation, a 
strong evidence-based recommendation could be made.
Is there a rationale for using crystalloids?
Compared to crystalloids, there are substantial drug 
acquisition costs for colloids [12]. Given the ever-rising 
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© 2010 BioMed Central Ltdcost of healthcare internationally, it is noteworthy that 
among the countries with the highest colloid utilization 
are those with government managed or socialized health-
care systems. Clinical indications aside, eﬀ  orts to control 
healthcare expenditures based upon drug acquisition 
costs alone may lead to greater expenses and worse 
clinical outcomes [13].
Colloids have a combination of desirable and un-
desirable eﬀ   ects. Among their most common adverse 
reactions are general allergic responses, which are not 
easily predicted and may result in anaphylaxis [3]. In 
addition, their general anti-thrombotic properties may 
adversely aﬀ   ect blood coagulation [3]. Hydroxyethyl 
starch solutions increase the risk of acute kidney injury in 
sepsis and albumin may cause harm in traumatic brain 
injury [14-16].
Of course, there are detrimental eﬀ  ects of crystalloids 
as well. Depending on the speciﬁ  c ﬂ  uid, they may cause 
hyperchloremic metabolic acidosis, hypocoagulable states, 
reduced renal blood ﬂ  ow and urine output, and neuro-
logic and gastrointestinal disturbances [17]. However, the 
clinical implications of these potentially adverse eﬀ  ects 
are not fully understood.
Why are we irrational?
Why do physicians behave irrationally in the face of 
clinical evidence that may guide appropriate decision-
making? In this example, why do certain regions of the 
world utilize colloids preferentially despite the lack of 
evidence to prove their superiority [1,2]? Although 
unlikely, it is possible that genetic diﬀ  erences in patients 
or regional diﬀ  erences in disease result in true previously 
unrecognized superiority. Variations in local prescribing 
practices are far more likely. For example, in antibiotic 
prescription for bacteremia, the country of origin and 
infectious diseases specialist input were explanatory 
factors [18]. In patients with septic shock, low dose 
corticosteroids are used in more than half of patients in 
Europe but less than one-quarter in Asia [19]. As has 
been shown within and across healthcare systems for 
myriad clinical decisions, clinical practice for ﬂ  uid 
choices varies despite available evidence.
According to the framework developed by Cabana and 
colleagues [20], barriers to optimum medical care exist in 
three major categories: knowledge, attitude and behavior. 
With globally available medical information, knowledge 
of evidence regarding ﬂ   uid resuscitation is not the 
primary barrier to evidence-based practice. Physicians’ 
practices are governed by attitudes that guideline 
recommendations may not produce the desired outcome, 
and cultural inertia restricting change in practice 
patterns. Attitude dictates prescribing behavior.
For all things clinical, the truth about ﬂ  uid resuscitation 
is inevitably in the middle. Perhaps some colloid use 
mixed with crystalloid use in certain patient populations 
is most beneﬁ  cial [21]. Previous clinical trials have led to 
that supposition, but we must wonder: if the ideal 
randomized, controlled trial deﬁ  nitively reported that as 
truth, would clinical practice change? Perhaps the answer 
is not more randomized clinical trials but better 
adherence to current guidelines and treatment 
recom mendations.
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